RT Journal Article
T1 The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.
A1 Heinrich, Daniel
A1 Bektic, Jasmin
A1 Bergman, Andries M
A1 Caffo, Orazio
A1 Cathomas, Richard
A1 Chi, Kim N
A1 Daugaard, Gedske
A1 Keizman, Daniel
A1 Kindblom, Jon
A1 Kramer, Gero
A1 Olmos, David
A1 Omlin, Aurelius
A1 Sridhar, Srikala S
A1 Tucci, Marcello
A1 van Oort, Inge
A1 Nilsson, Sten
K1 Bone metastases
K1 Patient selection
K1 Targeted alpha therapy
K1 Treatment monitoring
K1 Treatment sequence
AB Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided.
YR 2017
FD 2017-09-06
LK https://hdl.handle.net/10668/27740
UL https://hdl.handle.net/10668/27740
LA en
DS RISalud
RD Apr 4, 2025